Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,3165,340,28
Msft0,47
Nokia3,76053,85950,41
IBM0,66
Mercedes-Benz Group AG72,6872,7-0,55
PFE-0,31
10.06.2023 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 09.06.2023 22:00:00
Alnylam Pharm (ALNY.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
190,83 0,21 0,40 373 396
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.06.2023
Popis společnosti
Obecné informace
Název společnostiAlnylam Pharmaceuticals, Inc.
TickerALNY
Kmenové akcie:Ordinary Shares
RICALNY.O
ISIN-
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 31.12.2021 1 665
Akcie v oběhu k 30.06.2022 120 992 000
MěnaUSD
Kontaktní informace
Ulice675 W Kendall St
MěstoCAMBRIDGE
PSČ02142-1168
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 175 518 200
Fax16175518101

Business Summary: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Alnylam Pharmaceuticals, Inc. revenues increased 10% to $438.1M. Net loss increased 33% to $517.7M. Revenues reflect ONPATTRO segment increase of 35% to $290.4M, GIVLAARI segment increase of 45% to $80.4M, Europe segment increase of 27% to $131.5M, Rest of World segment increase of 71% to $48.9M.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 10.06.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardMichael Bonney6302.08.202102.08.2021
PresidentAkshay Vaishnaw5901.01.202207.01.2006
Chief Executive Officer, DirectorYvonne Greenstreet5901.01.202219.09.2016
Chief Financial Officer, Executive Vice PresidentJeffrey Poulton5413.08.201913.08.2019
Executive Vice President, Chief Legal Officer and SecretaryIndrani Franchini50
Chief Medical Officer, Executive Vice President, Development and Medical AffairsPushkal Garg54
Chief Commercial OfficerTolga Tanguler49